Van Wey, Metzler & Williams

Our Insights

3 minutes read

Increased Marketing of Pradaxa Means More Internal Bleeding Injuries

An estimated 3.2 million prescriptions have been written for Pradaxa, an anticoagulant (blood thinner) drug that has been shown to cause serious and even fatal internal bleeding injuries and deaths.

Pradaxa Manufacturer Targets Patients with Atrial Fibrillation

Pradaxa is manufactured by pharmaceutical giant Boehringer Ingelheim who recently launched a campaign to bring awareness to atrial fibrillation, a heart condition that causes irregular heartbeats and can lead to stroke. Part of their awareness campaign focuses on the benefits of Pradaxa, which Boehringer Ingelheim claims is superior in reducing strokes and hemorrhage compared to its older counterpart, Warfarin.

Boehringer Ingelheim even launched the GLORIA-AF patient registry, which it says will help doctors and pharmaceutical manufacturers better understand treatments like Pradaxa to reduce the risk of stroke.

Pradaxa Internal Bleeding Events High

According to data compiled by QuarterWatch, a publication of the Institute for Safe Medication Practices (ISMP), Pradaxa is one of the mostly highly reported medications for serious adverse reactions and death. In 2011 alone, the Food and Drug Administration (FDA) received more reports of adverse reactions to Pradaxa than to any other drug on the U.S. market, 3,781 in total.

Of those more than 3,000 adverse events reported with Pradaxa, more than 500 resulted in death, and more than 2,000 were serious internal bleeding events. In contrast, a total of 1,106 adverse events were reported with anticoagulant Warfarin, 72 of which resulted in death.

This high number of Pradaxa adverse events reported to the FDA has many experts and doctors concerned about patient safety. The FDA estimates that only one percent of all adverse drug reactions are actually reported to the agency, which would mean a sharply higher number of Pradaxa internal bleeding cases could be occurring.

Pradaxa Lacks an Antidote

One of the main reasons why doctors have been prescribing more patients Pradaxa is that they do not have to conduct extensive blood tests with Pradaxa. Also, the dosing for Pradaxa is much simpler than for Warfarin. But this simplicity comes at a price, because unlike Warfarin, Pradaxa has no antidote.

In fact, Boehringer Ingelheim began selling Pradaxa on the U.S. market in October 2010, knowing that they could not provide doctors with an antidote to the powerful drug and knowing that internal bleeding was a risk. Despite the negative press Pradaxa has received, Pradaxa continues to have a strong performance on the U.S. market, netting Boehringer Ingelheim sales of $17.1 billion in 2011 alone.

Pradaxa Internal Bleeding Claims

If you or a loved one has suffered internal bleeding while on Pradaxa, you may have a claim against the manufacturer. Dallas Pradaxa attorney Kay L. Van Wey has dedicated her career to helping consumers who have been injured by the actions large corporations.

Call Van Wey, Presby & Williams at (800) 489-5082 today for a free consultation regarding your legal options. 

By: Kay Van Wey | January 12th, 2016

back to Insights

We welcome your phone call or email

Contact Us Today!

To Discuss Your Case